NCT05746793 At High-risk for Pre-eclampsia After Assisted Reproductive Technology
| NCT ID | NCT05746793 |
| Status | Recruiting |
| Phase | — |
| Sponsor | CRG UZ Brussel |
| Condition | Pre-Eclampsia |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,050 participants |
| Start Date | 2023-02-15 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,050 participants in total. It began in 2023-02-15 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overarching goal of the project is to unravel PE etiopathogenesis in high-risk patients (PCOS patients and oocyte acceptors) after assisted reproductive technology (ART) to individualize prenatal care following ART and to determine potential targets for new PE prevention options decreasing the morbidity/mortality caused by this pathology. More specifically, the following objectives/work packages (WPs) are put forward: * WP1 - PRECONCEPTION: Identify preconceptional maternal characteristics associated with in-creased risk of PE in ART patients (1a) and investigate the potential role of the endometrium prior to pregnancy (1b). * WP2 - DURING PREGNANCY: Evaluate the Fetal Medicine Foundation's (FMF) first trimester PE screening in selected high-risk groups post ART to explore the clinical benefit in this specific context (2a) and investigate the association between parameters during the pregnancy and PE development post-ART. * WP3 - AT DELIVERY: Identifying placental molecular pathways associated with PE post-ART.
Eligibility Criteria
Inclusion Criteria: * First time oocyte acceptors Or Nulliparous PCOS patients undergoing ART (IVF/ICSI) * Criteria for PCOS: two out of the three following criteria must be present: 1. Oligo-or anovulation: a menstrual cycle \>35 days 2. Hyperandrogenism: * Clinically: the presence of hirsutism and/ or severe acne in combination with alopecia confirmed hyperandrogenism Or * Biochemically: serum total testosterone \>52 ng/dl or calculated free testosterone \>0,64 ng/dl 3. Polycystic ovaries: * Follicle number per ovary (FNPO) ≥ 12 on both ovaries Or * Ovarian volume ≥ 10 ml in both ovaries Or * One ovary with ≥ 20 follicles (Using endovaginal US transducers with a frequency bandwidth that includes 8 MHz) Or * AMH ≥ 4,9 ng/ml Exclusion Criteria: * Known essential hypertension or development of a new-onset hypertension before 20 weeks' gestation * Hypertension is defined as a systolic blood pressure ≥ 140 or a diastolic blood pressure ≥ 90 on two separate measurements with at least 20 minutes in between, taken when the patients is in a seated position Or * The patient is known with hypertension, diagnosed by a certified doctor * Known diabetes type 1 or 2 before pregnancy * Diagnosis of diabetes is confirmed when one of the following is present: * Fasting glucose ≥ 126 mg/dl * A 2-hour plasma glucose level ≥ 200 mg/dL during a 75-g oral glucose tolerance test Or * The patient is known with diabetes (type 1 or 2), diagnosed by a certified doctor * Thyroid dysfunction not under control with medication: * Hyperthyroidism, the diagnoses is made when: * Peripheral blood TSH \<0,5 mIU/L and fT4 \>1,9 ng/dl Or * When the patient is known with hyperthyroidism diagnosed by a certified physician * Hypothyroidism, the diagnosis is made when: * Peripheral blood TSH \>5 mIU/L and fT4 \<0,7 ng/dl Or * When the patient is known with hypothyroidism diagnosed by a certified physician * Other endocrinological disorder (including Cushing syndrome, Adrenal insufficiency, acromegaly): for diagnosis we will trust the opinion of the certified endocrinologist * Cardiovascular diseases (including coronary artery disease, arrhythmia, heart valve disease and heart failure): for diagnosis we will trust the opinion of the certified cardiologist * Renal disease/insufficiency: for diagnosis we will trust the opinion of the certified nephrologist * Systemic lupus erythematosus: for diagnosis we will trust the opinion of the certified internal medicine doctor * Antiphospholipid syndrome: for diagnosis we will trust the opinion of the certified internal medicine doctor * Liver dysfunction/disease: for diagnosis we will trust the opinion of the certified gastroenterologist * History of prior pre-eclampsia * Women pregnant with a fetus with known abnormalities such chromosomal anomalies, structural deformities of limbs or organs or any other prebirth diagnosed syndromes or defects * Multiple pregnancy
Contact & Investigator
Shari Mackens, PhD, MD
PRINCIPAL INVESTIGATOR
Medical director Brussels IVF
Frequently Asked Questions
Who can join the NCT05746793 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 48 Years, studying Pre-Eclampsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05746793 currently recruiting?
Yes, NCT05746793 is actively recruiting participants. Contact the research team at studieverpleegkundigen_crg@uzbrussel.be for enrollment information.
Where is the NCT05746793 trial being conducted?
This trial is being conducted at Brussels, Belgium.
Who is sponsoring the NCT05746793 clinical trial?
NCT05746793 is sponsored by CRG UZ Brussel. The principal investigator is Shari Mackens, PhD, MD at Medical director Brussels IVF. The trial plans to enroll 1,050 participants.